Volkan Korten - Infectious Diseases

Author Information

Volkan Korten is a distinguished researcher affiliated with the Department of Infectious Diseases and Clinical Microbiology at Marmara University Faculty of Medicine in Istanbul, Turkey. His work primarily focuses on infectious diseases, with a significant emphasis on viral infections such as COVID-19 and HIV. Through his contributions, he has played an integral role in advancing the understanding of infectious disease characteristics, transmission, and treatment.

Research Contributions

Volkan Korten has made substantial contributions to the field of infectious diseases, with a particular focus on the clinical characteristics and management of COVID-19. His recent work includes studies on the risk factors associated with severe COVID-19, the efficacy and safety of vaccines like CoronaVac, and the impact of treatments such as Tocilizumab in severe COVID-19 cases. Additionally, his research extends to the study of HIV, including health surveys and the diversity of HIV-1 subtypes and drug-resistance mutations. His work is vital in shaping public health responses and treatment protocols for infectious diseases.

Aliases

Volkan Korten is also known by several aliases in academic publications, including V Korten and V. Korten.

Publication and Citation Metrics

Metric	Value
Citation Count	2324
h-index	21
Paper Count	121

Publications:

Clinical characteristics and risk factors associated with severe disease and outcome of patients with COVID-19.

DOI: 10.3855/jidc.15411

Year: 2022

Comparison of Turkish version of the medical outcomes study-HIV health survey with short form health survey-36 in people living with human immunodeficiency virus.

DOI: 10.1002/hpm.3450

Year: 2022

Coronavirus Pandemic Clinical characteristics and risk factors associated with severe disease and outcome of patients with COVID-19

DOI:

Year: 2022

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

DOI: 10.1016/S0140-6736(21)01429-X

Year: 2021

Transmission of SARS-CoV-2 in Different Districts of a County in Istanbul, March to September 2020

DOI: 10.1177/10105395211009008

Year: 2021

Frequency and associated factors for carbapenem-non-susceptible Bacteroides fragilis group bacteria colonization in hospitalized patients: Case control study in a university hospital in Turkey.

DOI: 10.1016/j.ijmmb.2021.03.018

Year: 2021

The value of open-source clinical science in pandemic response: lessons from ISARIC

DOI: 10.1016/S1473-3099(21)00565-X

Year: 2021

Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls

DOI: 10.1007/s00296-021-04965-6

Year: 2021

Determination of fosfomycin susceptibility in carbapenemaseproducing K. pneumoniae strains isolated prior to clinical use of the intravenous formulation in Turkey

DOI: 10.5472/MARUMJ.942784

Year: 2021

Diversity of HIV-1 subtypes and transmitted drug-resistance mutations among minority HIV-1 variants in a Turkish cohort.

DOI: 10.2174/1570162X19666211119111740

Year: 2021

Who Should Not Receive the DTaP Vaccine?

What are B Cells?

How are Antimicrobials Administered?

Why is Drug Resistance a Concern?

What is Zika Virus?

What Other Diseases Do Anopheles Mosquitoes Transmit?

How Do Pathogens Evade Folate Inhibition?

What are the future directions in HIV research?

What Are Common Bacterial Infections?

What is Vaccine Hesitancy?

Partnered Content Networks

Relevant Topics